Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bebo HealthXPAR:MLBBO 54 EV-to-EBITDA is 25.90 as of Aug. 10, 2026, which is 79% above its 10-year median of 14.44. GuruFocus rates XPAR:MLBBO with a GF Score™ of 54/100 and a GF Value™ of €0.03 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 950 Retail - Cyclical companies, Bebo Health ranks worse than 86.95% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bebo Health's enterprise value is €132.50 Mil.
Bebo Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €5.12 Mil. Therefore, Bebo Health's EV-to-EBITDA for today is 25.90.
The historical rank and industry rank for Bebo Health's EV-to-EBITDA or its related term are showing as below:
XPAR:MLBBO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.45 Med: 14.44 Max: 248.78
Current: 25.9
During the past 7 years, the highest EV-to-EBITDA of Bebo Health was 248.78. The lowest was 5.45. And the median was 14.44.
XPAR:MLBBO's EV-to-EBITDA is ranked worse than 86.95% of 950
companies
in the Retail - Cyclical industry
Industry Median: 9.015
vs XPAR:MLBBO: 25.90
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bebo Health's PE Ratio (TTM) for today is calculated as:
Bebo Health's share price for today is €0.184.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bebo Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bebo Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:MLBBO vs CASY, WSM, ULTA: EV-to-EBITDA Comparison
For the Specialty Retail subindustry, Bebo Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bebo Health EV-to-EBITDA vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Bebo Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bebo Health's EV-to-EBITDA falls into.
Bebo Health's current Enterprise Value is €132.50 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bebo Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €5.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bebo Health (XPAR:MLBBO) has a EV-to-EBITDA of 25.90 as of Aug. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bebo Health. This is 79% above median its historical median of 14.44. Over the past decade, Bebo Health's EV-to-EBITDA has ranged from 5.45 to 248.78. According to the industry distribution chart, Bebo Health ranks #826 out of 950 companies in the Retail - Cyclical industry, placing it in the top 86.9%.
Is Bebo Health's EV-to-EBITDA too high?
Bebo Health's current EV-to-EBITDA of 25.90 is 79% above median its 10-year median of 14.44. Over the past 10 years, this metric has ranged from a low of 5.45 to a high of 248.78. The Retail - Cyclical industry median EV-to-EBITDA is 9.02. Bebo Health's value of 25.90 is 187.3% above this industry median. Based on the distribution chart, Bebo Health ranks #826 out of 950 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, Bebo Health has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bebo Health's EV-to-EBITDA compare to CASY and WSM?
According to the Retail - Cyclical industry distribution chart, Bebo Health ranks #826 out of 950 companies for EV-to-EBITDA. This places Bebo Health in the lower half of its industry. The industry median EV-to-EBITDA is 9.02. Bebo Health's value of 25.90 is 187.3% above this benchmark. Historically, Bebo Health's own EV-to-EBITDA has ranged from 5.45 to 248.78 over the past decade. While the company's 10-year median is 14.44 vs. the industry median of 9.02, Bebo Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Retail - Cyclical company?
The median EV-to-EBITDA among Retail - Cyclical companies is 9.02, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bebo Health's current EV-to-EBITDA of 25.90 is 187.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bebo Health. For the Retail - Cyclical industry, the median EV-to-EBITDA is 9.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bebo Health's current EV-to-EBITDA is 25.90, which is 79% above median its own 10-year median of 14.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bebo Health stock overvalued right now?
Based on GuruFocus' analysis, Bebo Health (XPAR:MLBBO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.18 — trading 513.3% above its estimated fair value. The current EV-to-EBITDA is 25.90, which is 79% above median its 10-year median of 14.44 and 187.3% above the Retail - Cyclical industry median of 9.02. Bebo Health's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bebo Health (XPAR:MLBBO), the current EV-to-EBITDA is 25.90 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bebo Health (XPAR:MLBBO) Overvalued in 2026?
Based on GuruFocus' analysis, Bebo Health stock appears to be overvalued.
The current stock price of €0.18 is trading 513.3% above its estimated GF Value™ of €0.03.
GuruFocus considers Bebo Health to be Significantly Overvalued.
Key valuation signals for XPAR:MLBBO:
EV-to-EBITDA: 25.90 (79% above median its 10-year median of 14.44)
GF Value™: €0.03 vs. price of €0.18 (513.3% above fair value)
Industry Position: 187.3% above the Retail - Cyclical median (#826 of 950)
No single metric tells the full story. See the XPAR:MLBBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLBBO has been successfully added to your 
